New York, NYNCT06494501Now EnrollingIRB Ready

Atherosclerotic Cardiovascular Disease Clinical Trial in New York, NY

Access cutting-edge atherosclerotic cardiovascular disease treatment through this phase 3 clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.

Sponsored by Icahn School of Medicine at Mount Sinai

Quick Self-Assessment

See if you qualify for this New York location

Preparing your pre-screening questions…

Expert Care in New York

Access atherosclerotic cardiovascular disease specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related atherosclerotic cardiovascular disease treatment provided free

Apply for This New York Location

Check if you qualify for this atherosclerotic cardiovascular disease clinical trial in New York, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New York

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New York site if eligible
  4. 4Begin participation

About This Atherosclerotic Cardiovascular Disease Study in New York

Despite increasing evidence that exposure to cardiovascular risk factors (CVRF) at an early age increases the prevalence of subclinical atherosclerosis and is associated with a greater risk of cardiovascular events later in life, there is a lack of randomized trial evidence to support primary prevention strategies in adults aged 30-50 years. The researchers have designed a randomized controlled trial to evaluate whether strict control of CVRF in young adults without known cardiovascular disease, will reduce the progression of total atherosclerosis burden, a surrogate endpoint for symptomatic cardiovascular disease, compared with usual care. The researchers propose a randomized controlled trial enrolling 1,600 healthy young adults who meet the inclusion criteria and who do not meet any exclusion criteria. Eligible study participants will be randomized, in a 1:1 ratio, to either the intervention group (active treatment strategy) or to the control group (guideline-directed medical therapy). Randomization will be stratified by the presence or absence of atherosclerotic plaque in vascular ultrasound.

Sponsor: Icahn School of Medicine at Mount Sinai

Who Can Participate

Inclusion Criteria

Male or female subjects between 30 to 50 years of age.
No prior history of coronary artery disease, cerebrovascular disease or peripheral artery disease.
Serum LDL-C \> 1.8 mmol/l (70 mg/dl).
Presence of subclinical atherosclerosis as assessed by 3DVUS or by the presence of coronary artery calcium (defined as coronary artery calcium score ≥25), independent of risk calculators; and/or high lifetime risk (≥30%) using the ASCVD calculator; and/or intermediate 10-year risk (≥7.5%) using the ASCVD calculator in the presence of 2 risk enhancers. The presence of atherosclerotic plaque by 3DVUS will be defined according to the PESA study definitions14: plaque is defined as a focal protrusion into the arterial lumen of thickness \>0.5 mm or \>50% if the intima media thickness or intima media thickness \>1.5 mm. CT scan for coronary artery calcium assessment will not be part of the protocol but will be used where available. Risk enhancers are defined as15:
Family history of premature atherosclerotic CVD
Persistently elevated LDL-C ≥ 160 mg/dl
Chronic kidney disease
Metabolic syndrome
Conditions specific to women (e.g. preeclampsia, premature menopause)
Inflammatory diseases (especially rheumatoid arthritis, psoriasis, HIV)
Ethnicity (e.g., South Asian ancestry)
Persistently elevated triglycerides (≥175 mg/dl)
Hs-CRP ≥2 mg/L
Lp(a) levels \>50 mg/dl
apoB ≥130 mg/dl
Ankle-brachial index \<0.9

Exclusion Criteria

Any uncontrolled or serious disease, or any medical or surgical condition, that may either interfere with participation in the clinical study, and/or put the subject at significant risk (according to investigator's \[or delegate\] judgment) if he/she participates in the clinical study.
An underlying known disease, or surgical, physical, or medical condition that, in the opinion of the investigator (or delegate) might interfere with interpretation of the clinical study results.
Females who are pregnant or nursing, or who are of childbearing potential and unwilling to use at least two methods of highly effective contraception (failure rate less than 1% per year) (e.g. combined oral contraceptives, barrier methods, approved contraceptive implant, long- term injectable contraception, or intrauterine device) for the entire duration of the study.
Severe concomitant non-cardiovascular disease that carries the risk of reducing life expectancy to less than 5 years.
History of malignancy that required surgery (excluding local and wide-local excision), radiation therapy and/or systemic therapy during the three years prior to randomization
Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver or unexplained elevations in ALT, aspartate aminotransferase (AST), \>3x the ULN, or total bilirubin \>2x ULN at screening confirmed by a repeat abnormal measurement at least 1 week apart.
Known contraindications to anti-lipid therapy
Known history of alcohol and/or drug abuse within the last 5 years.
Treatment with other investigational products or devices within 30 days or five half- lives of the screening visit, whichever is longer.
Planned use of other investigational products or devices during the course of the study.
Any condition that according to the investigator could interfere with the conduct of the study, such as but not limited to:
Subjects who are unable to communicate or to cooperate with the investigator.
Unable to understand the protocol requirements, instructions and study-related restrictions, the nature, scope, and possible consequences of the study (including subjects whose cooperation is doubtful due to drug abuse or alcohol dependency).
Unlikely to comply with the protocol requirements, instructions, and study- related restrictions (e.g., uncooperative attitude, inability to return for follow-up visits, and improbability of completing the study).
Have any medical or surgical condition, which in the opinion of the investigator would put the subject at increased risk from participating in the study.
Persons directly involved in the conduct of the study.
Treatment (within 90 days of screening) with monoclonal antibodies directed towards PCSK9.
History of hypersensitivity to the study treatment or its excipients or to other siRNA drugs.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New York?

Yes, this clinical trial (NCT06494501) has an active research site in New York, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Atherosclerotic Cardiovascular Disease Treatment Options in New York, NY

If you're searching for atherosclerotic cardiovascular disease treatment options in New York, NY, this clinical trial (NCT06494501) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New York research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced atherosclerotic cardiovascular disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all atherosclerotic cardiovascular disease clinical trials near you to find additional studies recruiting in your area.

More Heart Disease Trials in New York, NY

See all heart disease clinical trials recruiting in New York — not just this study.

Browse Heart Disease Trials in New York →

Browse More Trials by Condition

Heart Disease TrialsAnkylosing Spondylitis TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in New York?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New York, NY